Biocardia Cell Therapy To Enter PMDA Clinical Consultation
ReutersDec 16, 2025 1:42 PM
Dec 16 (Reuters) - BioCardia Inc BCDA.O:
BIOCARDIA CELL THERAPY FOR ISCHEMIC HEART FAILURE TO PROGRESS TO FORMAL CLINICAL CONSULTATION WITH JAPAN PMDA
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
Elon Musk’s SpaceX Poised for Record-Breaking IPO: How Can Retail Investors Get In on the Action of Starlink Stock?
TradingKey - Elon Musk's rocket manufacturer SpaceX is expected to launch an IPO in 2026, with a target IPO valuation projected to reach $1.5 trillion. However, prior to its listing, the stock can only be traded in the private market, characterized by low information transparency and high capital baTradingKey
Fri, Dec 19
Cathie Wood Predicts Bitcoin Has Bottomed. Is Now The Best Time to Buy? How to Buy BTC?
Purchasing Bitcoin is generally divided into three stages: pre-transaction, during transaction, and post-transaction. Each stage requires careful attention, as losses can easily arise from operational errors, pitfalls, and other factors.TradingKey
Fri, Dec 19
Japan Central Bank Rate Hike To Three-Decade High Imminent, How Will The Market Go? Which Assets Most Affected?
As global monetary policy divergence enters a critical phase, the Bank of Japan (BoJ) is anticipated to raise its benchmark interest rate at the monetary policy meeting on December 19, 2025, by 25 basis points to 0.75% , marking its highest level in nearly 30 years.TradingKey
Thu, Dec 18
Wall Street Sounds Alarm: "Bitcoin's Four-Year Cycle Invalidated" - Will the Crypto Bull Market Persist?
The crypto market is evolving into a more mature and rational phase, driven by shifting participant demographics and heightened macroeconomic influences, even as the validity of Bitcoin's four-year cycle remains uncertain.TradingKey
Fri, Dec 12
Tradingkey
